论文部分内容阅读
[目的]探讨拉米夫定治疗慢性乙型肝炎过程中,乙型肝炎病毒DNA聚合酶变异(HBVYMDD)的相关因素。[方法]采用实时荧光定量PCR基因扩增法对拉米夫定(100mg/d)抗病毒治疗连续2年中,出现HBVYMDD变异株的分析。[结果]82例乙肝患者使用拉米夫定治疗6～12个月发生变异者3例(3.66%,其中1例e抗原血清转换后HBV-DNA仍阳性);治疗18～24个月后发生变异者16例(19.51%),其中2例e抗原血清转换后HBV-DNA仍阳性。[结论]应用拉米夫定治疗慢性乙型肝炎,6个月后可出现HBVYMDD变异,随着治疗时间延长,其变异发生率越高,而e抗原血清转换率不高。
[Objective] To investigate the related factors of hepatitis B virus DNA polymerase mutation (HBVYMDD) during the treatment of chronic hepatitis B in lamivudine. [Method] Real-time fluorescent quantitative PCR gene amplification method for lamivudine (100mg / d) antiviral therapy for 2 consecutive years, the emergence of HBVYMDD variants. [Results] Three cases (3.66%) of HBV-DNA in 82 patients with hepatitis B who were treated with lamivudine for 6 to 12 months were still positive after 18 to 24 months of treatment Sixteen patients (19.51%) were mutated, of which two were still positive for HBV-DNA after e antigen seroconversion. [Conclusion] The HBV YMDD mutation may occur after 6 months in patients with chronic hepatitis B treated with lamivudine. The higher the mutation rate is, the lower the e antigen seroconversion rate with the prolongation of treatment time.